Veru announces positive phase 2 clinical data: efficacy of enobosarm therapy correlates with androgen receptor levels in ar+er+her2- metastatic breast cancer presented at the 2021 asco annual meeting

-- in phase 2 study, enobosarm, an oral selective androgen receptor (ar) agonist, had the most significant antitumor effects in heavily pretreated ar+er+ metastatic breast cancer subjects with ≥ 40% ar expression in cancer tissue -- -- companion diagnostic test to measure ar may be used to select ar+er+her2- metastatic breast cancer subjects most likely to benefit from enobosarm treatment--
VERU Ratings Summary
VERU Quant Ranking